List view / Grid view
Scientists from UNC-Chapel Hill and Princeton University in the United States, reveal key molecular details that hold promise for ultimate goal of heart disease reversal.
A new device that models atherosclerosis can help researchers better understand the disease, develop therapies and diagnose blood health...
Researchers have tested whether a single injection of the gene, LeXis could slow down the development of heart disease...
Measuring a blood marker, copeptin, can successfully predict the risk of heart attacks in people with type-2 diabetes.
In a Phase I clinical trial, heart failure patients treated with patches made from their muscle cells showed improved exercise capacity and heart function after one year. Stem cell patch-based therapy may be a viable heart failure therapy and should be validated in larger clinical trials, researchers conclude.
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
It is difficult to estimate the global burden of cardiovascular disease in people with diabetes, due to lack of data and standardisation...
8 July 2016 | By Victoria White, Digital Content Producer
Researchers were able to determine that Wars2 plays an important role in supplying sufficient endothelial cells for angiogenesis...
24 February 2016 | By Victoria White
Using a modified version of troponin C, researchers showed it can enhance or therapeutically preserve heart function and cardiovascular performance in mice...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
20 January 2016 | By Victoria White
Mucosis has secured the €3.7 million translational fund award from the Wellcome Trust to progress SynGEM into Phase I and IIa human clinical trials...
14 January 2016 | By Victoria White
Calibr's antibody fusion technology provides a proprietary, modular approach to developing long-acting biotherapeutics based on peptide and protein agonists and antagonists...
6 January 2016 | By Victoria White
Researchers tested the drug, commonly used to treat leukaemia, in zebrafish bred to carry Duchenne muscular dystrophy and recorded a 40% improvement in the condition of the fish...
5 January 2016 | By Victoria White
Renova and Research Development Foundation (RDF) have entered into a worldwide exclusive license agreement for RDF's portfolio of urocortin and stresscopin genes, as well as select peptides and proteins...
22 December 2015 | By Victoria White
The IMI has launched two Calls for proposals that will advance drug development in Ebola, childhood cancers, neurological disorders, and eye disease...
21 December 2015 | By Victoria White
Bayer and CRISPR Therapeutics are to form the joint venture to discover, develop and commercialise new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease...
